Glenmark Pharmaceuticals Inc., USA (Glenmark) and Glenmark Pharmaceuticals Limited have reached a settlement agreement with Pfizer Inc., PF Prism C.V., and PF Prism IMB B.V. (Pfizer) for Axitinib tablets, 1 mg and 5 mg, the generic version of their Inlyta tablets, 1 mg and 5 mg.
Glenmark had previously announced it received tentative approval by the United States Food & Drug Administration (FDA) for their generic Axitinib tablets, 1 mg and 5 mg on November 30, 2020.
According to IQVIA sales data for the 12-month period ending September 2022, the Inlyta tablets, 1 mg and 5 mg market2 achieved annual sales of approximately $644.5 million.
Glenmark
